MedTrace Logo

Combining PET/CT and EBV DNA to Evaluate the Hazard of Progression in the Follow-up of Locally Advanced NPC

NCT03601390 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 387

Last updated 2020-12-19

No results posted yet for this study

Summary

PET/CT and EBV DNA are important in diagnosis of NPC. We consider that combining post-treament PET/CT and plasma EBV DNA may be effective in evaluating the hazard of progression in the follow-up of Locally Advanced Nasopharyngeal Carcinoma. Hence we establish this prospective cohort study.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DEVICE

PET/CT and EBV DNA

PET/CT and EBV DNA will be proformed after the IMRT treatment

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Haiqiang Mai, Dr · Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2019-12-12
Completion
2020-12-12
FDA Device
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03601390 on ClinicalTrials.gov